Mounjaro®
Starting from £179.99/mo
Start journey Learn moreThere is no legitimate way to get discount codes, vouchers or cashback on Mounjaro in the UK. As a prescription-only medicine, Mounjaro cannot legally be advertised to the public, and offering financial incentives tied to purchasing a POM would breach UK medicines regulations. That said, understanding what the real costs involve — and what a fair private price should include — is genuinely useful. This page covers exactly that, so you can make a confident decision rather than chase a deal that may not exist or may not be safe.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Mounjaro is a Prescription-Only Medicine regulated under the Human Medicines Regulations 2012. The MHRA's position is clear: GLP-1 medicines are not assessed or promoted for quick or cosmetic weight loss, and advertising POMs to the public is prohibited. That prohibition extends to promotional pricing tied to the medicine itself, which is why you will not find a genuine Mounjaro discount code from any legitimate pharmacy or clinic.
This is not a commercial choice by Eli Lilly or pharmacies; it is the legal framework that keeps prescription medicines from being marketed like consumer goods. When you do see what looks like money off Mounjaro in the UK (a social-media code, a referral discount, a time-limited deal) that is a warning sign rather than a bargain. The MHRA has seized around 20 million doses of illegally traded weight-loss medicines worth roughly £45 million, including counterfeit tirzepatide pens discovered at an illicit manufacturing site in Northampton in October 2025. Fake pens have in some cases contained insulin, with serious consequences for people who injected them expecting something else entirely. Suspect sellers can be reported directly to the MHRA via Yellow Card.
A quick habit worth building: before using any online pharmacy, spend thirty seconds checking its registration at the GPhC register. If it is not listed, walk away.
After Eli Lilly's list price increase in September 2025, private providers have adjusted their prices accordingly. As widely reported, the highest dose now carries a list price of around £330 per four-week pen; across the full range of doses and providers, private monthly prices typically sit somewhere between £149 and £375. That spread sounds wide, but the reason is not the medicine itself, it is what different providers bundle in or leave out.
Some headline prices cover the pen and nothing else. A consultation fee, a prescription fee, and delivery can be added separately, nudging the real total well above what the listing suggested. A thorough breakdown of what Mounjaro genuinely costs privately in the UK is worth reading before you compare providers, because the comparison only makes sense once you are comparing like with like.
At nume, one price covers the clinical consultation, the prescription review by a GPhC-registered Independent Prescriber, the treatment, and free next-working-day tracked delivery. No separate fees. No subscriptions. Every repeat order is clinically re-reviewed before it is dispatched. That structure is not the cheapest you will find, and that is a deliberate choice, not an oversight.
Tirzepatide treatment begins at 2.5mg, a dose whose purpose is to let your system adjust gradually, not to produce maximum effect straight away. The prescriber will typically assess whether to increase to 5mg after four weeks, then continue through the licensed schedule at a pace that suits your response and tolerability. Lower doses do generally cost less per pen, which means early months of treatment are usually the least expensive point in the programme.
What that also means is that comparing quotes at different stages of treatment requires some care. A price quoted for 2.5mg will look very different from one at 10mg or 12.5mg. If a provider quotes you a low headline figure, it is worth asking which dose that covers, sometimes a starter-dose price is used to draw a comparison that shifts considerably once you move up. You can read more about the broader clinical profile of tirzepatide and what the evidence says about how the medicine works at each stage.
NICE's recommendation for tirzepatide (TA1026, published December 2024) gives prescribers and patients a reference framework for NHS access, but private treatment follows the licensed eligibility criteria in the SmPC rather than NICE's specific NHS commissioning thresholds. Either way, a prescriber reviews your full picture (BMI, weight-related conditions, medical history) before any treatment is confirmed. That review is the thing that keeps you safe; it is not a formality to be bypassed in exchange for a lower price.
Life intervenes. People take breaks from treatment for surgery, pregnancy planning, or simply to reassess. Understanding what happens during a break from Mounjaro and how coming off tirzepatide works is clinically relevant, and it also has a cost dimension, because restarting after a gap may require going back to a lower dose depending on how long you have been off treatment.
There is no subscription model with nume, sorry, with our Mounjaro service. Every order goes through a fresh clinical review, and there is no auto-renewal charging you while you are on a break. If you are thinking about stepping down your dose gradually rather than stopping abruptly, that is a conversation to have with your prescriber; the Patient Information Leaflet and your clinical team are the right guides, not a cost-saving shortcut. The FAQs page covers some of the common practical questions that come up around pausing and restarting.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.